IL-23 inhibitors are class of biologics that inhibit the P 19 subunit of IL-23 and reduce the activities of the Th17 pathway.
These agents approved to treat plaque psoriasis include: guselkumab, tildrakizumab, risankizumab and mirkikizumab.
These agents have acceptable safety profiles, and convenient infrequent dosing schedules.
IL-23 inhibitors have no increase in serious infections or malignancy.
Upper respiratory tract infections and injection site reactions are the most frequent reported adverse reactions.